Skip to main content
Download PDF

Anti-Toxoplasma gondii effects of XYP1-derived peptides and regulatory mechanisms of XYP1

Parasites & Vectors volume 17, Article number: 376 (2024) Cite this article

Abstract

Background

Toxoplasmosis, caused by Toxoplasma gondii , poses serious health issues for humans and animals. Individuals with impaired immune systems are more susceptible to severe toxoplasmosis. Pregnant women infected by T. gondii can face the possibility of birth defects and miscarriages. While pyrimethamine and sulfadiazine are commonly used drugs in clinical practice, concerns over their side effects and resistance are on the rise. A spider peptide XYP1 isolated from Lycosa coelestis had potent anti-T. gondii effects, but it had a high synthesis cost and strong cytotoxicity.

Methods

This study intended to modify XYP1 for producing derived peptides via amino acid truncation and substitution. The anti-T. gondii effect was evaluated by trypan blue staining assay and killing experiment of RH strain tachyzoites. The CCK8 and hemolysis assays were used to compare their safeties. The morphological changes of T. gondii were observed by scanning electron microscope and transmission electron microscope. In addition, the mechanism of XYP1 against T. gondii through RNA-sequencing was further explored.

Results

In vivo and in vitro experiments revealed that XYP1-18 and XYP1-18-1 had excellent anti-T. gondii activity with lower cytotoxicity and hemolysis activity than XYP1. XYP1, XYP1-18, and XYP1-18-1 were able to disrupt the surface membrane integrity of T. gondii tachyzoites, forming pores and causing the disruption of organelles. Furthermore, RNA-sequencing analysis indicated that XYP1 could stimulate the host immune response to effectively eliminate T. gondii and lessen the host’s inflammatory reaction.

Conclusions

XYP1-18 had lower cytotoxicity and hemolysis activity than XYP1, as well as significantly extending the survival time of the mice. XYP1 played a role in host inflammation and immune responses, revealing its potential mechanism. Our research provided valuable insights into the development and application of peptide-based drugs, offering novel strategies and directions for treating toxoplasmosis.

Graphical Abstract

Background

Toxoplasma gondii (T. gondii) is an important opportunistic pathogen belonging to the phylum Apicomplexa. T. gondii can cause toxoplasmosis, which is a zoonotic parasitic disease affecting both humans and animals [1]. Globally, approximately one-third of the population is estimated to be infected with T. gondii [1, 2]. In immunocompromised patients, T. gondii infection can lead to significant morbidity and mortality. Currently, drugs such as pyrimethamine combined with sulfadiazine, trimethoprim combined with sulfamethoxazole, and spiramycin are mainly used in clinical treatment of toxoplasmosis [3, 4]. While these treatments can alleviate symptoms and control the disease, the limitations and side effects of drug treatment need to be taken into account [5]. T. gondii also showed increasing resistance to sulfadiazine and pyrimethamine [6]. Therefore, it is crucial to explore new treatment methods and drugs for the effective management of toxoplasmosis.

In recent years, peptide drugs have emerged as a novel therapeutic approach with various applications such as antiinflammatory, antitumor, and antimicrobial properties, making them valuable in treating a wide range of diseases [7,8,9]. Peptides offer the advantage of specific targeting toward diseases while reducing the complexity of toxic side effects and drug metabolism, thus becoming a new focus in drug research for treating multiple diseases. Studies have identified peptides with anti-T. gondii activity. For instance, cal14.1a was a peptide extracted from Conus californicus, which can reduce the invasion and proliferation of T. gondii in host cells [10]. Additionally, longicin P4, an alkaline peptide extracted from Haemaphysalis longicornis, had shown efficacy in limiting the growth of T. gondii [11]. HPRP-A1 and HPRP-A2, α-helical cationic peptides extracted from Helicobacter pylori, can effectively reduce the survival rate of T. gondii tachyzoites and inhibit their adhesion and invasion of macrophages [12]. These indicated that peptides still hold great potential and application space in the fight against T. gondii infection.

Our earlier studies have indicated that a novel spider polypeptide XYP1 derived from the venom of Lycosa coelestis suppressed the invasion and proliferation of T. gondii and extended the survival time of mice infected with T. gondii [13]. Compared with the conventional drug sulfadiazine, the peptide XYP1 showed superior therapeutic efficacy and fewer side effects, thus holding significant promise for the treatment of T. gondii infection. However, limitations such as strong cytotoxicity and high synthesis cost restricted its clinical application.

Peptide truncation can not only save the synthesis cost, reduce reaction time, and enhance efficiency, but also can alter the bioactivity, stability, hydrophilicity, hydrophobicity, and toxicity of peptides. The beneficial effects of peptide truncation have been reflected in arasin 1 and linear chicken β-defensin-4 [14,15,16]. The distribution of hydrophobic and hydrophilic residues is a crucial factor influencing the activity of antimicrobial peptides (AMPs), with hydrophilic residues typically concentrated near the membrane surface of AMPs, while hydrophobic residues are distributed internally. This distribution pattern facilitates the interaction of AMPs with the cell membrane, so as to enhance their bactericidal activity [17, 18].

In this study, XYP1 was truncated and replaced with amino acids to produce eight derived peptides. Two peptides, XYP1-18 and XYP1-18-1, with high anti-T. gondii activity were selected. XYP1-18 and XYP1-18-1 exhibited lower cytotoxicity and hemolysis compared with XYP1. Further in vivo and in vitro experiments indicated that XYP1-18 had similar activity as XYP1. The three peptides can damage the surface membrane and internal structure of T. gondii tachyzoites to different degrees. Additionally, we discovered that XYP1 can protect the host by reducing the inflammatory response and inducing immune response during T. gondii infection. In conclusion, our strategy may provide more insights and possibilities for peptide drug design and development, offering a novel approach for utilizing peptides to combat T. gondii infection in the future.

Methods

Parasites and cell culture

Tachyzoites of the RH-GFP-TgAtg8 and RH wild-type T. gondii strains were transmitted in human foreskin fibroblasts (HFFs). HFFs were growth in Dulbecco’s modified Eagle’s medium (DMEM, Gibco, USA) attached with 1% antibiotics (10 mg/mL streptomycin solution, 25 μg/mL amphotericin B, and 10,000 U/mL penicillin) (Sangon Biotech, China) and 10% fetal bovine serum (FBS, Invitrogen, USA) at 37 ℃ with the concentration of 5% CO2. The different T. gondii strains were maintained in HFFs with DMEM, 2% FBS, and 1% antibiotics in the same environment [19].

Animals

The 6–8-week-old female BALB/c and Kunming mice used in this study were purchased from the Department of Laboratory Animals, Central South University in China.

Sequence and structure analysis of polypeptides

The various characteristics of polypeptides including isoelectric point, net charge, and average hydrophilicity were analyzed on the website (https://www.expasy.org/) [20]. The tertiary structure of polypeptides was predicted by I-TASSER's online tool (http://zhanglab.ccmb.med.umich.edu/I-TASSER/) [21]. The spiral round figure was constructed by Heliquest online website (http://heliquest.ipmc.cnrs.fr/) [22].

Chemical synthesis and identification of XYP1-derived peptides

The derived peptides were synthesized by Fmoc solid phase polypeptide synthesis method [23]. It mainly included the following steps: deprotection of Fmoc group, coupling reaction, washing, detection using the Kaiser method, and cleavage. High performance liquid chromatography (HPLC) technique (Shimadzu, Japan) was used to purify peptides, and electrospray ionization mass spectrometry (ESI–MS) (Shimadzu, Japan) was used to identification of derived peptides.

Evaluation of anti-toxoplasma gondii effect

When T. gondii died, trypan blue was able to cross its cell membrane and enter the interior, making it blue. Trypan blue exclusion test was undertaken as mentioned before [24]. Firstly, 10 μM different XYP1-derived peptides were prepared, incubated with T. gondii for 2 h, and then the trypan blue dye was added. After 3–5 min, the survival rate of T. gondii was observed by optical microscope and the mortality rate was calculated.

The tachyzoites of RH-GFP-TgAtg8 strain did not fluorescein after death, which can be used to determine the difference in the anti-T. gondii activity of XYP1 and its derived peptides; 10 μM different derived peptides were incubated with tachyzoites of RH-GFP-TgAtg8 strain, respectively, and the fluorescence intensity and area were observed under fluorescence microscope (Leica DM IL LED, Germany).

Hemolysis and cytotoxicity assays

The hemolytic activity of peptides was determined by the amount of hemoglobin released from lysed human red blood cells [25]. Normal human blood was mixed 1:1 with Aldrin’s fluid, followed by centrifuging, and phosphate buffered saline (PBS) was added to make 1% red blood cell resuspension. The 50 μL resuspension was mixed with 50 μL PBS, 1% Triton X-100, 70% DMSO (Sigma, USA), and different concentrations of polypeptides, then incubated at 37 ℃ for 30 min. After centrifugation, the OD540 value of the supernatant was measured by Microplate reader (Agilent, USA) and the hemolysis rate was calculated.

The CCK-8 method [26] was employed to assess the effect of different peptides on cytotoxicity, and 100 μL of cell culture solution containing 10 μM different peptides were added to each of the 96-well plates. After 24 h, 10 μL CCK-8 solution (APExBIO, USA) was added and incubated for another 2 h. The OD540 value was then measured and the cell mortality was calculated.

Survival assay

The anti-T. gondii effect of peptides in vivo was investigated through a mouse survival experiment [27]. The experiment was divided into a PBS control group and different polypeptide groups. Each group of mice was intraperitoneally injected with 1000 RH strain tachyzoites. After 4 h, the pre-prepared 4 mg/mL peptides were injected into the mice. The survival time of mice in each group was recorded and analyzed statistically.

Electron microscopy technology

The scanning electron microscope (SEM) was used to observe the surface structure of T. gondii, while the transmission electron microscope (TEM) can reflect the morphological changes of T. gondii inside the cell [28]. The sample preparation process for SEM included: the preparation process of SEM consists of fixing the T. gondii sample with 4% glutaraldehyde solution and staying overnight at 4 ℃. A series of gradient dehydration treatments are performed, followed by dehydration in anhydrous ethanol. After dehydration, the tachyzoites were dried and coated, followed by SEM observation (Hitachi S-3400N, Japan).

TEM steps mainly include fixing, rinsing, dehydration, infiltration, embedding, etc. After the T. gondii samples were fixed in 4% glutaraldehyde, they were washed with a cacodylate buffer, and 1% osmium tetroxide was used to fix the sample at 4 ℃ for 2 h. The fixed samples were then washed and subjected to a series of gradient dewatering treatments before being embedded in epoxy resin and polymerized at 60 ℃. After polymerization, the sample was sliced and double stained. Finally, the internal structure of T. gondii tachyzoites treated with different polypeptides was observed by TEM (Tecnai G2 Spirit TWIN, USA).

RNA-seq analysis

The control group consisted of HFF cells infected with T. gondii without XYP1, and the experimental group was treated with XYP1 for 8 h. Total RNAs were extracted from the control and experimental groups and reverse to cDNA, with three replicates per group. After the steps of end repair, A-tailing, and adapter ligation, the samples were proceeded with polymerase chain reaction (PCR) amplification and Illumina transcriptome sequencing in the OE biotech Co., Ltd. (Shanghai, China). Trimmomatic software [29] was used to filter the raw data to obtain high-quality data information. Subsequently, the filtered data was aligned and assembled using HISAT2 [30] and StringTie [31] tool. The number of reads mapped to each gene in each sample was calculated.

DESeq software [31] was used to screen differentially expressed genes, and the screening conditions for differential genes were fold change > 2 and P value < 0.05. To further understand the function of differentially expressed genes, cluster analysis, gene ontology (GO) functional enrichment analysis [32] and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis [33] were conducted on the selected genes. Additionally, the PPI network of differentially expressed proteins was constructed by the STRING website, and hub genes were identified by Cytoscape software.

Quantitative real-time PCR (qRT-PCR)

The total RNAs from different samples were extracted using the classical Trizol method. The PerfectStart Uni RT&qPCR Kit (TransGen Biotech, China) was used to efficiently reverse transcribe RNA into cDNA and synthesize the first strand. The qRT-PCR reaction system contains cDNA temple, forward and reverse primers, double stranded DNA fluorescent dye (SYBR Green I), DNA polymerase, dNTP and buffer. The PCR reaction was performed using a two-step amplification procedure: 94 ℃ for 30 s (pre-denaturation) followed by 40 cycles of 94 ℃ for 5 s and 60 ℃ for 30 s. Finally, the relative expression of each gene was calculated by 2−∆∆Cq method.

Statistical analysis

The quantitative data was analyzed with the method of two-tailed Student’s t-test or two-way analysis of variance (ANOVA) with Tukey’s multiple comparisons in GraphPad 8.4 software. A P-value < 0.05 was considered to have a significant difference.

Results

Sequence analysis and structural modification of XYP1

XYP1, as a novel anti-T. gondii polypeptide, showed good anti-T. gondii activity [13]. To further reduce the cytotoxicity and synthetic cost of XYP1, bioinformatic analyses and structural modifications were performed to optimize the structure and function of XYP1. On the basis of the predicted tertiary structure of XYP1 (KIKWFKAMKSIAKFIAKDQLKKHL, Fig. 1A), the α-helix structure of the N-terminal was retained and truncated from the C-terminal, resulting in four truncated peptides: XYP1-15, XYP1-16, XYP1-17, and XYP1-18 (Fig. 1). The structure with hydrophobic and hydrophilic residues distributed on both sides is beneficial for enhancing the activity of antimicrobial peptides (AMPs). Therefore, according to the helical wheel projection diagrams of the truncated peptides, the amino acid substitutions were performed on the four peptides. Specifically, leucine (Leu, L) instead of lysine (Lys, K), K instead of isoleucine (Ile, I), K instead of alanine (Ala, A), serine (Ser, S) was replaced with K, phenylalanine (Phe, F) was replaced with lysine (K), and aspartic acid (Asp, D) was replaced with leucine (L). As shown in Fig. 1, four peptides were eventually generated: XYP1-15-1 (LKKWFKKMKKIAKKI), XYP1-16-1 (LKKWFKKMKKIAKKIA), XYP1-17-1 (LKKWFKKMKKIAKKIAK), and XYP1-18-1 (LKKWFKKMKKIAKKIAKL). The properties and parameters of XYP1 and its derived peptides were shown in Additional file 1: Table S1. The high-purity polypeptides were successfully synthesized by solid-phase synthesis. The results of ESI–MS (Additional file 1: Figs. S1 and S2) showed that the actual molecular weight of each polypeptide was consistent with the theoretical molecular weight.

Fig. 1
figure 1

Structure diagram of XYP1 and its derived peptides. A The predicted tertiary structure diagram of XYP1, the dotted red boxes are the amino acids intended to be truncated. B The whole diagram is divided into four small pictures, with the left being the structure diagram and spiral wheel diagram of XYP1-15, and the right being the schematic diagram of XYP1-15-1; the residues after amino acid replacement of XYP1-15 are marked in blue. C The left diagram is the structure diagram and spiral wheel diagram of XYP1-16, and the right diagram exhibits XYP1-16-1; the residues after amino acid replacement of XYP1-16 are marked in blue. D The diagram on the left describes the structure and properties of XYP1-17, and the right diagram represents XYP1-17-1; blue marks the amino acids that have been replaced. E The figures on the left and right show the structure and properties of the derived peptides XYP1-18 and XYP1-18-1, respectively

Full size image

The derived peptides XYP1-17, XYP1-18, and XYP1-18-1 exhibited anti-T. gondii activity

Our previous study has confirmed that 10 μM XYP1 can kill T. gondii tachyzoites. Therefore, trypan blue staining assay was used to compare the killing activity in vitro of 10 μM different derived peptides and XYP1. The result of XYP1 was consistent with the previous findings. Among these derived peptides, XYP1-17, XYP1-18, and XYP1-18-1 also exhibited good anti-T. gondii activity, with XYP1-18 being comparable to XYP1 (Fig. 2A). To further demonstrate the anti-T. gondii activity of XYP1-17, XYP1-17-1, XYP1-18, and XYP1-18-1, the tachyzoites of RH-GFP-TgAtg8 T. gondii strain were co-incubated with 10 μM concentrations of these peptides. After a 2-h incubation, we observed their anti-T. gondii activity through fluorescence microscopy (Fig. 2B). The fluorescence area and intensity of XYP1-17, XYP1-18, and XYP1-18-1 groups were significantly reduced compared with the control group (Fig. 2C, D). These results were consistent with the trypan blue staining assay.

Fig. 2
figure 2

Inhibitory effect of XYP1 and its derived peptides on T. gondii in vitro. A Statistical diagram of toxoplasma mortality in each group in trypan blue experiment, the killing effect of PBS (negative control group), DMSO (negative control group), and XYP1 and its derived peptides (experimental group) on T. gondii at a concentration of 10 μM. *P < 0.05, **P < 0.01, ##P < 0.01, ***P < 0.001, ****P < 0.0001, “ns” shows P > 0.05. B Fluorescence microscopy results of control group and XYP1 and derived peptides (XYP1-17, XYP1-18, XYP1-18-1), scale = 100 μm. C–D Statistical analysis of fluorescence area and fluorescence intensity of each group, *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, “ns” shows P > 0.05

Full size image

To explore the concentration dependence of the polypeptides against T. gondii, XYP1-derived peptide solutions with different concentration gradients (5 μM, 10 μM, 20 μM) were prepared and then mixed with T. gondii tachyzoites at room temperature. After incubation for 2 h, the anti-T. gondii effect was observed by fluorescence microscopy. The results showed that the killing effect of these three peptides on tachyzoites of RH-GFP-TgAtg8 strain was enhanced with increasing concentration (Fig. 3A), and the fluorescence density of T. gondii became weaker (Fig. 3B). Compared with the control group, the fluorescence intensity and fluorescence area of XYP1 and XYP1-18 at different concentrations were statistically different.

Fig. 3
figure 3

Safety assessment and survival experiments of XYP1-derived peptides. A, B The killing effect of derived peptides on T. gondii at different concentrations; Fig. A is the statistical analysis of fluorescence area of each group, Fig. B is the statistical analysis of fluorescence intensity of each group. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, “ns” shows P > 0.05. C Cytotoxic effects of XYP1, XYP1-18, and XYP1-18-1 at different concentrations on HFFs; each graph shows the IC50 value of each polypeptide to the HFFs. D Hemolytic activity of XYP1, XYP1-18, and XYP1-18-1 polypeptides on human red blood cells, hemolysis rate is a measure of hemolytic activity. E Survival of mice infected with T. gondii after treatment with three peptides: XYP1, XYP1-18, and XYP1-18-1, all drugs were administered to mice at a dose of 4 mg/kg, *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, “ns” shows P > 0.05

Full size image

The security of XYP1-18 and XYP1-18-1 was higher than XYP1

According to the results of trypan blue staining and fluorescence microscopy, the peptides XYP1-18 and XYP1-18-1 had better anti-T. gondii effects. Therefore, these two peptides were selected for the cytotoxicity test. It was observed that the higher the concentration of XYP1, XYP1-18, and XYP1-18-1, the greater the toxicity to cells (Fig. 3C). The IC50 values of XYP1, XYP1-18, and XYP1-18-1 were 33.63 μM, 80.60 μM, and 45.60 μM, respectively. The IC50 values of XYP1-18 and XYP1-18-1 were higher than XYP1, indicating higher safety of these two derived peptides.

Hemolysis assay was also used to evaluate the toxic effects of peptides on the host. When XYP1 concentrations ranged from 1.25 μM to 10 μM, almost no hemolysis reaction was observed. However, as the concentration increased, the hemolysis rate gradually increased (Fig. 3D). In contrast, XYP1-18 caused almost no hemolysis at concentrations ranging from 1.25 μM to 80 μM, and only minor hemolysis occurred even at the highest concentration (160 μM). XYP1-18-1 had low hemolysis at 1.25 μM to 160 μM, with a maximum hemolysis rate of only 20% (Fig. 3D). It was indicated that XYP1-18 and XYP1-18-1 were safer than XYP1 over a wider range of concentrations.

The efficacy of XYP1-18 in vivo was comparable to XYP1

The survival experiment was used to evaluate the therapeutic efficacy of several peptides against T. gondii infection in vivo. All mice in the control group died at 127.1 h. In contrast, XYP1 can significantly prolong the survival of mice to 208.5 h, XYP1-18 can be extended to 191 h, and XYP1-18-1 can only be extended to 145 h (Fig. 3E). There is no significant difference between XYP1-18 and XYP1. XYP1-18-1 group had poor effect on prolonging the survival time of mice.

XYP1-18 and XYP1-18-1 can destroy the surface structure and organelles of T. gondii

The effects of XYP1, XYP1-18, and XYP1-18-1 on the surface structure of T. gondii tachyzoites were observed using SEM. Normal T. gondii tachyzoites were crescent-shaped, with a sharp front end and a rounded back end (Fig. 4A, B). The cell membrane was complete and there were many micropores on the surface. After being treated with 10 μM polypeptides for 2 h, various damages were observed on the surface membranes of tachyzoites. In the XYP1 group, pores formed on the cell membrane surface, and many tachyzoites occurred wrinkling or expansion of the membrane (Fig. 4C, D). Under the influence of XYP1-18, many tachyzoites disintegrated, with depressions appearing on the cell membrane surface (Fig. 4E, F). XYP1-18-1 caused the pores or depressions on the surface of the T. gondii cell membranes, and some tachyzoites disintegrated (Fig. 4G, H). These results indicated that the three peptides had varying degrees of impact on the surface morphology of T. gondii. Specifically, XYP1-18 and XYP1-18-1 had more pronounced destructive effects on T. gondii than XYP1.

Fig. 4
figure 4

The SEM results of XYP1, XYP1-18, and XYP1-18-1 effects on the surface structure of T. gondii tachyzoites. A, B T. gondii tachyzoites were incubated with PBS buffer for 2 h. C, D T. gondii tachyzoites were incubated with XYP1 (10 μM) solution for 2 h. E, F T. gondii tachyzoites were incubated with XYP1-18 (10 μM) solution for 2 h. G, H T. gondii tachyzoites were incubated with XYP1-18-1 (10 μM) solution for 2 h. ↓: micropore; → : holes; ☆: shrunken or sunken tachyzoites of T. gondii; *: disintegrating T. gondii tachyzoites; enlarged tachyzoite. Scale: A = 10 μm; B = 2 μm; C = 10 μm; D = 2 μm; E = 5 μm; F = 2 μm; G = 5 μm; H = 2 μm

Full size image

TEM was used to observe the organelle structure inside T. gondii. The organelles inside the untreated tachyzoites were intact (Fig. 5A, B). In the XYP1 group, the tachyzoites not only showed ruptures in the surface membrane, but also different degrees of vacuolization internally (Fig. 5C, D). With the treatment of XYP1-18, the majority of tachyzoites exhibited not only severe deformation and rupture of the surface membrane, but also serious shrinkage and vacuolization internally (Fig. 5E, F). In the XYP1-18-1 group, the internal structure of tachyzoites was even more severely damaged, with not only shrinkage and vacuolization, but also complete dissolution of the tachyzoites observed (Fig. 5G, H). In conclusion, these polypeptides had varying degrees of impact on the internal structure of T. gondii tachyzoites.

Fig. 5
figure 5

The TEM results of XYP1, XYP1-18, and XYP1-18-1 effects on the internal structure of tachyzoites of T. gondii. A, B T. gondii tachyzoites were incubated with PBS buffer for 2 h. C, D T. gondii tachyzoites were incubated with XYP1 (10 μM) solution for 2 h. E, F T. gondii tachyzoites were incubated with XYP1-18 (10 μM) solution for 2 h. G, H T. gondii tachyzoites were incubated with XYP1-18-1 (10 μM) solution for 2 h. Co: conoid; Dg: electron-dense granule; Go: Golgi complex; Lb: lipid body; Nu: nucleus; Nm: nuclear membrane. Scale: A = 2 μm; B = 2 μm; C = 2 μm; D = 2 μm; E = 10 μm; F = 2 μm; G = 10 μm; H = 5 μm

Full size image

XYP1 affected the inflammatory and immune responses of host cells

Previous studies have initially explored the effects of XYP1 on T. gondii-related genes and pathways. To better understand the host cell response to T. gondii under the influence of XYP1, changes in genes and pathways before and after XYP1 treatment were analyzed by transcriptome technology. P < 0.05 and fold change > 2 were used to determine whether genes in the control group and the XYP1 group showed differential expression. A total of 65 genes had significant differences in expression, including 7 up-regulated genes and 58 down-regulated genes (Fig. 6A). The M-versus-A (MA) map and volcano map represented significantly differential genes under differential screening conditions (Fig. 6B, Additional file 1: Fig. S3A). After clustering analysis of the differentially expressed genes (Fig. 6C), it was observed that the samples from the control group and the XYP1 group clustered together in the same cluster, indicating that these genes exhibited similar expression patterns in the two sample groups and may have similar biological functions.

Fig. 6
figure 6

Effects of XYP1 on genes and pathways associated with host cells infected with T. gondii. A The number of differential genes up-regulated and down-regulated. B In the differentially expressed volcano map, green and red dots represent significantly different genes, and gray dots represent nonsignificantly different genes. C The results of cluster analysis for each difference group. Red indicates highly expressed genes, blue indicates genes that are low expression. D GO enrichment analysis Top30 bar chart. The horizontal coordinate is the GO entry name and the vertical coordinate is −log10 P-value. E Distribution of differentially expressed genes and all genes in KEGG pathway. The horizontal axis is the ratio (%) between the genes annotated to each metabolic pathway and the total number of genes annotated to the KEGG pathway. F Bubble diagram of KEGG enrichment Top20, entries with larger bubbles contain more differential protein coding genes, and the redder the bubble color, the greater the difference

Full size image

The 37 differentially expressed genes were classified into 3 main gene ontology (GO) categories, which were further assigned to 64 specific functional subcategories. As shown in Additional file 1: Fig. S3B, a total of 448 significantly enriched GO terms were identified. Among them, 310 terms were enriched in biological process (BP), 65 terms in cellular component (CC), and 73 terms in molecular function (MF). In the top 30 GO terms (Fig. 6D), the most significantly enriched term in BP was “inflammatory response,” in CC it was “vesicle,” and in MF it was “GTPase activity.” The KEGG enrichment results were summarized in Fig. 6E. Immune-related pathways with a higher gene enrichment included the IL-17 signaling pathway, tumor necrosis factor signaling pathway, cytokine-cytokine receptor interaction, NOD(Nucleotide oligomerization domain)-like receptor signaling pathway, and NF-kappa B signaling pathway. The top 20 significantly enriched pathways were selected from the KEGG enrichment results for display in a bubble chart, as shown in Fig. 6F.

Furthermore, protein–protein interaction (PPI) networks were mapped and the core interaction networks were predicted. As shown in Fig. 7A, a darker green color indicates higher score of the nodes. MCC, DMNC, and radiality algorithms are used to screen the Top20 hub proteins (Fig. 7B–D). The redder the color is, the higher the score of the nodes, and the more yellow–green the color is, the lower the score. In the MCC algorithm, the top three proteins were IL1B, IL-6, and CXCL-8; in the DMNC algorithm, the top three proteins were CCL-8, CSF3, and CXCL3; in the radiality algorithm, the top three proteins were IL1B, IL-6, and CXCL-8, consistent with the MCC results. Subsequently, the intersection was taken and a Venn diagram was plotted (Fig. 7E), showing 19 common hub proteins (Additional file 1: Table S2). MMC and radiality shared IL1B. There is ENTPD1 in the DMNC algorithm that has no intersection with the other two algorithms. The results of qPCR showed that the transcription levels of IL-17 and TP53 were down-regulated and NF-kB was up-regulated in the XYP1 treatment group (Fig. 7F–H).

Fig. 7
figure 7

Differential expression protein interaction network analysis and qPCR validation. A Circular protein interaction network map of differentially expressed genes, the darker the green color, the higher the node score. B The top 20 hub genes based on MMC algorithm. C The top 20 hub genes based on DMNC algorithm. D The top 20 hub genes based on radiality algorithm. E Venn diagram of hub genes intersection of three algorithms. F–H Changes in transcription levels of IL-17, tp53, and NF-κB genes

Full size image

Discussion

When T. gondii infects humans, it often remains inapparent, but those with congenital infections or compromised immune systems may suffer severe symptoms [34, 35]. The development of novel drugs is a current research focus, and venom peptides derived from animal toxins hold great potential as scaffolds for clinical applications, including cysteine-stabilized peptides and linear helical peptides [36]. In this study, eight derived peptides were successfully generated by amino acid truncation and replacement of XYP1, which originates from the venom of Lycosa coelestis. Preliminary results suggested that XYP1 might exert anti-T. gondii effect on the basis of an α-helical structure [13]. Phospholipids serve as a major source of negative charge in cell membranes, and active peptides with an α-helical structure often target phospholipids [37]. Therefore, the α-helix structure of the derived peptide is preserved. Because these peptides contain positively charged amino acid side chains, they can interact with phospholipids on the cell membrane by electrostatic interaction. The amphipathic α-helical structure formed by the peptides facilitates their insertion into the cell membrane [38]. When the peptide inserts into the cell membrane, its hydrophobic regions interact with the phospholipid bilayer, disrupting the integrity of the cell membrane, which leads to the formation of pores and gaps. These pores and gaps facilitate the leakage of cellular contents, thereby disrupting cellular homeostasis [39, 40].

Another essential property of AMPs is amphipathy, which refers to the relative abundance of hydrophilic and hydrophobic residues. Studies have shown that indolicidin analogs with increased amphipathy and charge displayed lower hemolytic activity and maintained antimicrobial activity [41, 42]. The distribution of hydrophobic and hydrophilic residues on both sides of the polypeptide plays a crucial role in the biological activity and bioavailability of AMPs [17]. By replacing individual amino acid residues, we successfully generated four new peptides that were structurally similar to truncated peptides but had more evenly distributed hydrophilic and hydrophobic residues, which may enhance their biological activity.

The initial screening experiments revealed that three peptides, XYP1-17, XYP1-18, and XYP1-18-1, exhibited much strong anti-T. gondii effects than the control group. Among them, XYP1-18 had similar anti-T. gondii activity to XYP1, while the other peptides had minimal effects. The lack of efficiency in XYP1-15 and XYP1-16 could be attributed to the absence of key functional residues induced by a greater number of truncated amino acids. Cationic amino acids, such as lysine (Lys) or arginine (Arg), are crucial for antimicrobial activity in peptide sequences. These common cationic amino acids are typically positioned on the hydrophilic side of the antimicrobial peptides [43,44,45]. There is a complex interaction among net charge, hydrophobicity, and amphipathicity [46,47,48,49]. These parameters play different roles in various peptide sequences, with optimal antimicrobial activity requiring the right balance of hydrophobicity, amphipathicity, and charge density. The truncated XYP1-15 and XYP1-16 significantly increased hydrophobicity and decreased net charge, while excessive hydrophobicity led to increased cytotoxicity and loss of activity, and decreased net charge may lead to decreased activity. Although the amphiphilicity and net charge of XYP1-15-1 and XYP1-16-1 increased, their hydrophobicity decreased, which may affect their anti-T. gondii activity.

The main difference between XYP1-17-1 and XYP1-18-1 were the lack of a leucine residue. Typically, higher hydrophobic leucine (Leu, L) can be substituted for lower hydrophobic amino acid residues to compensate for this loss [50,51,52]. Leucine side chains are relatively large, containing an isopropyl group that contributes to hydrophobic effects. These effects are crucial in protein folding and maintaining the structure of α-helices [53]. Further in vitro screening experiments had shown that XYP1-18 and XYP1-18-1 were the most effective derived-peptides, with lower cytotoxicity and hemolytic activity than XYP1, thus they have better potential as candidates for polypeptide therapy in toxoplasmosis.

We previously discovered that XYP1 can significantly down-regulate the MIC10, HSP29, and rpb-10 genes in T. gondii, which was associated with membrane component, invasion, and proliferation of T. gondii. However, it remains unclear how XYP1 affects the interactions between T. gondii and the host. In this study, RNA-seq was used to focus on the differential genes in the host before and after XYP1 treatment. In total, 65 genes showed significant differences in expression, with 7 up-regulated (10.77%) and 58 down-regulated (89.23%) genes. According to GO analysis, the most enriched biological process is the inflammatory response. Genes involved in this process include ADORA2A, NFKBIZ, ELF3, and TNIP3. This suggested that XYP1 may eliminate T. gondii by modulating the host cell’s immune system to trigger inflammatory response and immune response. When host cells were infected with T. gondii, it activated the immune system, leading to the release of inflammatory cytokines such as IL-6, IL-1β, IL-12, and TNF-α. These cytokines promote inflammation, activating the host cell’s immune function to combat T. gondii [54,55,56,57,58]. The NF-κB is a driver of inflammation response, and NFKBIZ is an inhibitor of NF-κB [59]. Our findings revealed that XYP1 may kill T. gondii by up-regulating the NF-κB regulated pathway. Additionally, on the basis of KEGG analysis, we found that the most significantly enriched pathways among down-regulated genes were the IL-17 signaling pathway, cytokine–cytokine receptor interaction, and TNF signaling pathway. The down-regulation of IL-17 was verified by qRT-PCR assay (Fig. 7F). IL-17 production was associated with protective and pathogenic responses during T. gondii infection [60]. Thus, XYP1 might down-regulate the host cell IL-17 signaling pathway, reducing host pathological responses. These pathways were crucial for regulating various biological processes via cell-to-cell interactions and signals.

To sum up, the study of XYP1-derived peptides provided a promising treatment approach for T. gondii infection, with great potential for clinical application. While considerable progress has been made, there remain hurdles to overcome. For example, the use of peptide drugs has limitations such as a short half-life. Therefore, future research should focus on improving the properties and effectiveness of peptides to enhance their clinical value. Additionally, further investigation is needed to explore how XYP1 specifically regulates the immune response in host cells to better understand its anti-T. gondii mechanisms. In summary, this study lays the groundwork for the development of new anti-T. gondii drugs and offers important insights for the research and usage of peptide-based drugs.

Conclusions

This study successfully identified two derived peptides, XYP1-18 and XYP1-18-1, with anti-T. gondii activity through modifying XYP1. In comparison with the parent XYP1, these peptides exhibited lower cost and improved safety (low cytotoxicity and hemolytic activity). Survival assay results demonstrated that XYP1-18-1 also can prolong the survival time of T. gondii-infected mice. Furthermore, XYP1 can eliminate T. gondii by modulating the inflammatory and immune response of host cells. These discoveries provided a novel strategy and direction for treating T. gondii infection, as well as useful references for the development and application of peptide-based therapies.

Availability of data and materials

The HPLC and ESI–MS results of peptides generated during the current study is stored in the Figshare repository, ***:. The RNA-Seq data have been deposited in the Genome Sequence Archive (Genomics, Proteomics & Bioinformatics 2021) in National Genomics Data Center (Nucleic Acids Res 2022), China National Center for Bioinformation/Beijing Institute of Genomics, and Chinese Academy of Sciences (GSA-Human: HRA007277), and are publicly accessible at https://ngdc.cncb.ac.cn/gsa-human.

Abbreviations

AMP:

Antimicrobial peptide

CCL:

C-C motif chemokine

CSF:

Colony-stimulating factor

CXCL:

C-X-C motif chemokine ligand

DMEM:

Dulbecco’s modified Eagle’s medium

DMSO:

Dimethyl sulfoxide

ESI–MS:

Electrospray Ionization mass spectrometry

FBS:

Fetal bovine serum

HFF:

Human foreskin fibroblast cell

HPLC:

High-performance liquid chromatography

IL:

Interleukin

OD:

Optical density

PBS:

Phosphate buffered saline

SEM:

Scanning electron microscope

TEM:

Transmission electron microscope

TP53:

Tumor protein 53

References

  1. Montoya JG, Liesenfeld O. Toxoplasmosis. Lancet. 2004;363:1965–76. https://doi.org/10.1016/s0140-6736(04)16412-x.

    Article  CAS  PubMed  Google Scholar 

  2. Flegr J, Prandota J, Sovičková M, Israili ZH. Toxoplasmosis–A global threat. Correlation of latent toxoplasmosis with specific disease burden in a set of 88 countries. PLoS ONE. 2014;9:e90203. https://doi.org/10.1371/journal.pone.0090203.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Alday PH, Doggett JS. Drugs in development for toxoplasmosis: advances, challenges, and current status. Drug Des Devel Ther. 2017;11:273–93. https://doi.org/10.2147/dddt.S60973.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Zhang JL, Si HF, Sun JC, Lv K, Yan BQ, Li B, et al. Determination of myrislignan levels in BALB/c mouse plasma by LC-MS/MS and a comparison of its pharmacokinetics after oral and intraperitoneal administration. BMC Vet Res. 2021;17:275. https://doi.org/10.1186/s12917-021-02990-y.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Shammaa AM, Powell TG, Benmerzouga I. Adverse outcomes associated with the treatment of Toxoplasma infections. Sci Rep. 2021;11:1035. https://doi.org/10.1038/s41598-020-80569-7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Doliwa C, Xia D, Escotte-Binet S, Newsham EL, Sanya JS, Aubert D, et al. Identification of differentially expressed proteins in sulfadiazine resistant and sensitive strains of Toxoplasma gondii using difference-gel electrophoresis (DIGE). Int J Parasitol Drugs Drug Resist. 2013;3:35–44. https://doi.org/10.1016/j.ijpddr.2012.12.002.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Wang JJ, Dou XJ, Song J, Lyu YF, Zhu X, Xu L, et al. Antimicrobial peptides: promising alternatives in the post feeding antibiotic era. Med Res Rev. 2019;39:831–59. https://doi.org/10.1002/med.21542.

    Article  CAS  PubMed  Google Scholar 

  8. Ramazi S, Mohammadi N, Allahverdi A, Khalili E, Abdolmaleki P. A review on antimicrobial peptides databases and the computational tools. Database. 2022:baac011. https://doi.org/10.1093/database/baac011.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Ahmed TAE, Hammami R. Recent insights into structure-function relationships of antimicrobial peptides. J Food Biochem. 2019;43:e12546. https://doi.org/10.1111/jfbc.12546.

    Article  PubMed  Google Scholar 

  10. De León-Nava MA, Romero-Núñez E, Luna-Nophal A, Bernáldez-Sarabia J, Sánchez-Campos LN, Licea-Navarro AF, et al. In vitro effect of the synthetic cal14.1a Conotoxin, derived from Conus californicus, on the Human Parasite Toxoplasma gondii. Mar Drugs. 2016;14:66. https://doi.org/10.3390/md14040066.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Tanaka T, Maeda H, Matsuo T, Boldbattar D, Umemiya-Shirafuji R, Kume A, et al. Parasiticidal activity of Haemaphysalis longicornis longicin P4 peptide against Toxoplasma gondii. Peptides. 2012;34:242–50. https://doi.org/10.1016/j.peptides.2011.07.027.

    Article  CAS  PubMed  Google Scholar 

  12. Liu R, Ni Y, Song J, Xu Z, Qiu J, Wang L, et al. Research on the effect and mechanism of antimicrobial peptides HPRP-A1/A2 work against Toxoplasma gondii infection. Parasite Immunol. 2019;41:e12619. https://doi.org/10.1111/pim.12619.

    Article  CAS  PubMed  Google Scholar 

  13. Liu Y, Tang Y, Tang X, Wu M, Hou S, Liu X, et al. Anti-Toxoplasma gondii effects of a novel spider peptide XYP1 in vitro and in vivo. Biomedicines. 2021;9:934. https://doi.org/10.3390/biomedicines9080934.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Paulsen VS, Blencke HM, Benincasa M, Haug T, Eksteen JJ, Styrvold OB, et al. Structure-activity relationships of the antimicrobial peptide arasin 1 - and mode of action studies of the N-terminal, proline-rich region. PLoS ONE. 2013;8:e53326. https://doi.org/10.1371/journal.pone.0053326.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Dong N, Ma QQ, Shan AS, Lv YF, Hu W, Gu Y, et al. Novel design of short antimicrobial peptides derived from the bactericidal domain of avian β-defensin-4. Protein Pept Lett. 2012;19:1212–9. https://doi.org/10.2174/092986612803217006.

    Article  CAS  PubMed  Google Scholar 

  16. Dong N, Ma QQ, Shan AS, Wang L, Sun WY, Li YZ. Influence of truncation of avian β-defensin-4 on biological activity and peptide-membrane interaction. Protein Pept Lett. 2012;19:430–8. https://doi.org/10.2174/092986612799789323.

    Article  CAS  PubMed  Google Scholar 

  17. Sani MA, Separovic F. How membrane-active peptides get into lipid membranes. Acc Chem Res. 2016;49:1130–8. https://doi.org/10.1021/acs.accounts.6b00074.

    Article  CAS  PubMed  Google Scholar 

  18. Lei J, Sun LC, Huang SY, Zhu CH, Li P, He J, et al. The antimicrobial peptides and their potential clinical applications. Am J Transl Res. 2019;11:3919–31.

    CAS  PubMed  PubMed Central  Google Scholar 

  19. Dawant T, Wang W, Spriggs M, Magela de Faria Junior G, Horton L, Szafranski NM, et al. Isolation of Toxoplasma gondii in cell culture: an alternative to bioassay. Int J Parasitol. 2024;54(3–4):131–137. https://doi.org/10.1016/j.ijpara.2023.12.002.

    Article  PubMed  Google Scholar 

  20. Duvaud S, Gabella C, Lisacek F, Stockinger H, Ioannidis V, Durinx C. Expasy, the Swiss bioinformatics resource portal, as designed by its users. Nucleic Acids Res. 2021;49:W216–27. https://doi.org/10.1093/nar/gkab225.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Zhou X, Zheng W, Li Y, Pearce R, Zhang CX, Bell EW, et al. I-TASSER-MTD: a deep-learning-based platform for multi-domain protein structure and function prediction. Nat Protoc. 2022;17:2326–53. https://doi.org/10.1038/s41596-022-00728-0.

    Article  CAS  PubMed  Google Scholar 

  22. Gautier R, Douguet D, Antonny B, Drin G. HELIQUEST: a web server to screen sequences with specific alpha-helical properties. Bioinformatics. 2008;24:2101–2. https://doi.org/10.1093/bioinformatics/btn392.

    Article  CAS  PubMed  Google Scholar 

  23. Hansen PR, Oddo A. Fmoc solid-phase peptide synthesis. Methods Mol Biol. 2015;1348:33–50. https://doi.org/10.1007/978-1-4939-2999-3_5.

    Article  CAS  PubMed  Google Scholar 

  24. Nguyen TT, Kamyingkird K, Phimpraphai W, Inpankaew T. Viability of Toxoplasma gondii tachyzoites in different conditions for parasite transportation. Vet World. 2022;15:198–204. https://doi.org/10.14202/vetworld.2022.198-204.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Stark M, Liu LP, Deber CM. Cationic hydrophobic peptides with antimicrobial activity. Antimicrob Agents Chemother. 2002;46:3585–90. https://doi.org/10.1128/aac.46.11.3585-3590.2002.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. You FT, Li C, Zhang SC, Zhang QS, Hu ZY, Wang YH, et al. Sitagliptin inhibits the survival, stemness and autophagy of glioma cells, and enhances temozolomide cytotoxicity. Biomed Pharmacother. 2023;162:114555. https://doi.org/10.1016/j.biopha.2023.114555.

    Article  CAS  PubMed  Google Scholar 

  27. Li ZH, Li C, Szajnman SH, Rodriguez JB, Moreno SNJ. Synergistic activity between statins and bisphosphonates against acute experimental toxoplasmosis. Antimicrob Agents Chemother. 2017;61(8):e02628–16. https://doi.org/10.1128/aac.02628-16.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Si HF, Xu CY, Zhang JL, Zhang XK, Li B, Zhou XZ, et al. Licochalcone A: an effective and low-toxicity compound against Toxoplasma gondii in vitro and in vivo. Int J Parasitol Drugs Drug Resist. 2018;8:238–45. https://doi.org/10.1016/j.ijpddr.2018.02.006.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Bolger AM, Lohse M, Usadel B. Trimmomatic: a flexible trimmer for Illumina sequence data. Bioinformatics. 2014;30:2114–20. https://doi.org/10.1093/bioinformatics/btu170.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Kim D, Langmead B, Salzberg SL. HISAT: a fast spliced aligner with low memory requirements. Nat Methods. 2015;12:357–60. https://doi.org/10.1038/nmeth.3317.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Pertea M, Pertea GM, Antonescu CM, Chang TC, Mendell JT, Salzberg SL. StringTie enables improved reconstruction of a transcriptome from RNA-seq reads. Nat Biotechnol. 2015;33:290–5. https://doi.org/10.1038/nbt.3122.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Resource TGO. 20 years and still GOing strong. Nucleic Acids Res. 2019;47:D330–8. https://doi.org/10.1093/nar/gky1055.

    Article  CAS  Google Scholar 

  33. Kanehisa M, Furumichi M, Sato Y, Kawashima M, Ishiguro-Watanabe M. KEGG for taxonomy-based analysis of pathways and genomes. Nucleic Acids Res. 2023;51:D587–92. https://doi.org/10.1093/nar/gkac963.

    Article  CAS  PubMed  Google Scholar 

  34. Eza DE, Lucas SB. Fulminant toxoplasmosis causing fatal pneumonitis and myocarditis. HIV Med. 2006;7:415–20. https://doi.org/10.1111/j.1468-1293.2006.00393.x.

    Article  CAS  PubMed  Google Scholar 

  35. Dubey JP, Murata FHA, Cerqueira-Cézar CK, Kwok OCH, Villena I. Congenital toxoplasmosis in humans: an update of worldwide rate of congenital infections. Parasitology. 2021;148:1406–16. https://doi.org/10.1017/s0031182021001013.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Rádis-Baptista G. Cell-penetrating peptides derived from animal venoms and toxins. Toxins. 2021;13:147. https://doi.org/10.3390/toxins13020147.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Bolhassani A, Jafarzade BS, Mardani G. In vitro and in vivo delivery of therapeutic proteins using cell penetrating peptides. Peptides. 2017;87:50–63. https://doi.org/10.1016/j.peptides.2016.11.011.

    Article  CAS  PubMed  Google Scholar 

  38. Torres MDT, Sothiselvam S, Lu TK, de la Fuente-Nunez C. Peptide design principles for antimicrobial applications. J Mol Biol. 2019;431:3547–67. https://doi.org/10.1016/j.jmb.2018.12.015.

    Article  CAS  PubMed  Google Scholar 

  39. Langenegger N, Nentwig W, Kuhn-Nentwig L. Spider venom: components, modes of action, and novel strategies in transcriptomic and proteomic analyses. Toxins. 2019;11:611. https://doi.org/10.3390/toxins11100611.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Zhang C, Yang M. Antimicrobial peptides: from design to clinical application. Antibiotics. 2022;11:349. https://doi.org/10.3390/antibiotics11030349.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Falla TJ, Hancock RE. Improved activity of a synthetic indolicidin analog. Antimicrob Agents Chemother. 1997;41:771–5. https://doi.org/10.1128/aac.41.4.771.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Smirnova MP, Afonin VG, Shpen VM, Tiagotin IV, Kolodkin NI. [Structure-function relationship between analogues of the antibacterial peptide indolicidin. I. Synthesis and biological activity of analogues with increased amphipathicity and elevated net positive charge of the molecule]. Bioorg Khim. 2004;30:458–65. https://doi.org/10.1023/b:rubi.0000043782.21640.c2.

    Article  CAS  PubMed  Google Scholar 

  43. Wang JJ, Chou SL, Yang ZY, Yang Y, Wang ZH, Song J, et al. Combating drug-resistant fungi with novel imperfectly amphipathic palindromic peptides. J Med Chem. 2018;61:3889–907. https://doi.org/10.1021/acs.jmedchem.7b01729.

    Article  CAS  PubMed  Google Scholar 

  44. Zhu X, Dong N, Wang ZY, Ma Z, Zhang LC, Ma QQ, et al. Design of imperfectly amphipathic α-helical antimicrobial peptides with enhanced cell selectivity. Acta Biomater. 2014;10:244–57. https://doi.org/10.1016/j.actbio.2013.08.043.

    Article  CAS  PubMed  Google Scholar 

  45. Cutrona KJ, Kaufman BA, Figueroa DM, Elmore DE. Role of arginine and lysine in the antimicrobial mechanism of histone-derived antimicrobial peptides. FEBS Lett. 2015;589:3915–20. https://doi.org/10.1016/j.febslet.2015.11.002.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Magana M, Pushpanathan M, Santos AL, Leanse L, Fernandez M, Ioannidis A, et al. The value of antimicrobial peptides in the age of resistance. Lancet Infect Dis. 2020;20:e216–30. https://doi.org/10.1016/s1473-3099(20)30327-3.

    Article  CAS  PubMed  Google Scholar 

  47. Kindrachuk J, Napper S. Structure-activity relationships of multifunctional host defence peptides. Mini Rev Med Chem. 2010;10:596–614. https://doi.org/10.2174/138955710791383983.

    Article  CAS  PubMed  Google Scholar 

  48. Rosenfeld Y, Lev N, Shai Y. Effect of the hydrophobicity to net positive charge ratio on antibacterial and anti-endotoxin activities of structurally similar antimicrobial peptides. Biochemistry. 2010;49:853–61. https://doi.org/10.1021/bi900724x.

    Article  CAS  PubMed  Google Scholar 

  49. Li SA, Xiang Y, Wang YJ, Liu J, Lee WH, Zhang Y. Naturally occurring antimicrobial peptide OH-CATH30 selectively regulates the innate immune response to protect against sepsis. J Med Chem. 2013;56:9136–45. https://doi.org/10.1021/jm401134n.

    Article  CAS  PubMed  Google Scholar 

  50. Yin LM, Edwards MA, Li J, Yip CM, Deber CM. Roles of hydrophobicity and charge distribution of cationic antimicrobial peptides in peptide-membrane interactions. J Biol Chem. 2012;287:7738–45. https://doi.org/10.1074/jbc.M111.303602.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Chen Y, Guarnieri MT, Vasil AI, Vasil ML, Mant CT, Hodges RS. Role of peptide hydrophobicity in the mechanism of action of alpha-helical antimicrobial peptides. Antimicrob Agents Chemother. 2007;51:1398–406. https://doi.org/10.1128/aac.00925-06.

    Article  CAS  PubMed  Google Scholar 

  52. Azmi S, Srivastava S, Mishra NN, Tripathi JK, Shukla PK, Ghosh JK. Characterization of antimicrobial, cytotoxic, and antiendotoxin properties of short peptides with different hydrophobic amino acids at “a” and “d” positions of a heptad repeat sequence. J Med Chem. 2013;56:924–39. https://doi.org/10.1021/jm301407k.

    Article  CAS  PubMed  Google Scholar 

  53. Zhu BY, Zhou NE, Kay CM, Hodges RS. Packing and hydrophobicity effects on protein folding and stability: effects of beta-branched amino acids, valine and isoleucine, on the formation and stability of two-stranded alpha-helical coiled coils/leucine zippers. Protein Sci. 1993;2:383–94. https://doi.org/10.1002/pro.5560020310.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Li DY, Wu MH. Pattern recognition receptors in health and diseases. Signal Transduct Target Ther. 2021;6:291. https://doi.org/10.1038/s41392-021-00687-0.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Quinn SR, O’Neill LA. A trio of microRNAs that control Toll-like receptor signalling. Int Immunol. 2011;23:421–5. https://doi.org/10.1093/intimm/dxr034.

    Article  CAS  PubMed  Google Scholar 

  56. Scanga CA, Aliberti J, Jankovic D, Tilloy F, Bennouna S, Denkers EY, et al. Cutting edge: MyD88 is required for resistance to Toxoplasma gondii infection and regulates parasite-induced IL-12 production by dendritic cells. J Immunol. 2002;168:5997–6001. https://doi.org/10.4049/jimmunol.168.12.5997.

    Article  CAS  PubMed  Google Scholar 

  57. Deckert-Schlüter M, Albrecht S, Hof H, Wiestler OD, Schlüter D. Dynamics of the intracerebral and splenic cytokine mRNA production in Toxoplasma gondii-resistant and -susceptible congenic strains of mice. Immunology. 1995;85:408–18.

    PubMed  PubMed Central  Google Scholar 

  58. Nagineni CN, Pardhasaradhi K, Martins MC, Detrick B, Hooks JJ. Mechanisms of interferon-induced inhibition of Toxoplasma gondii replication in human retinal pigment epithelial cells. Infect Immun. 1996;64:4188–96. https://doi.org/10.1128/iai.64.10.4188-4196.1996.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Coto E, Reguero JR, Avanzas P, Pascual I, Martín M, Hevia S, et al. Gene variants in the NF-KB pathway (NFKB1, NFKBIA, NFKBIZ) and risk for early-onset coronary artery disease. Immunol Lett. 2019;208:39–43. https://doi.org/10.1016/j.imlet.2019.02.007.

    Article  CAS  PubMed  Google Scholar 

  60. Hunter CA, Sibley LD. Modulation of innate immunity by Toxoplasma gondii virulence effectors. Nat Rev Microbiol. 2012;10:766–78. https://doi.org/10.1038/nrmicro2858.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

We express our gratitude to all participants involved in this research.

Funding

The work was supported by the National Natural Science Foundation of China (32170510) and Hunan graduate research innovation project (QL20230021).

Author information

Author notes

  1. Jing Li and Kaijuan Wu contributed equally to this work.

Authors and Affiliations

  1. Department of Parasitology, School of Basic Medical Sciences, Central South University, Changsha, 410013, Hunan, China

    Jing Li, Kaijuan Wu, Xiaohua Liu, Dongqian Yang, Jing Xie, Yixiao Wang, Kang Liu & Liping Jiang

  2. China-Africa Research Center of Infectious Diseases, Central South University, Changsha, 410013, Hunan, China

    Liping Jiang

  3. Department of Vascular Surgery, The Third Xiangya Hospital, Central South University, Changsha, 410013, Hunan, China

    Zheng Wang

  4. Hunan Key Laboratory of Traditional Chinese Veterinary Medicine, Hunan Agricultural University, Changsha, 410128, China

    Wei Liu

Authors
  1. Jing Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kaijuan Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Xiaohua Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Dongqian Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jing Xie
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yixiao Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Kang Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Zheng Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Wei Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Liping Jiang
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

L.J., J.L., and K.W. participated in the conception and design of this study. J.L., K.W., X.L., D.Y., J.X., Y.W., and K.L. performed the experiments and analyzed the results. Z.W. and W.L. provided guidance and advice on transcriptome analysis. J.L. and K.W. wrote the manuscript. L.J. reviewed the manuscript and acquired the funding support. All authors made contributions to the final version and approved the submission.

Corresponding author

Correspondence to Liping Jiang.

Ethics declarations

Ethics approval and consent to participate

This study was approved by the Ethics Committee of the School of Basic Medical Science, Central South University, Changsha, China (protocol code: 2020KT-11), and complied with national regulations on the ethical treatment of experimental animals.

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Additional file 1: Table S1.

The properties and parameters of XYP1 and its derived peptide. Table S2. The hub proteins of intersection of three algorithms. Figure S1. The ESI–MS results of XYP1-15, XYP1-15-1, XYP1-16, XYP1-16-1. The abscissa is the mass charge ratio (m/z), and the ordinate is the ionic strength. Figure S2. The ESI–MS results of XYP1-17, XYP1-17-1, XYP1-18, XYP1-18-1. Figure S3. GO enrichment analysis of differential genes. (A) MA map of differentially expressed genes. The X-axis is the normalized average expression of genes in all samples involved in the comparison, and the Y-axis is log2Fold Change. Red indicates significant differential genes. (B) Comparison map of differentially expressed genes and distribution of all genes at GO level. Blue represents all the gene-enriched GO entries, red represents the differential gene-enriched GO entries, horizontal axis represents the entry name, and vertical axis represents the number of genes corresponding to the entry and its percentage.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Li, J., Wu, K., Liu, X. et al. Anti-Toxoplasma gondii effects of XYP1-derived peptides and regulatory mechanisms of XYP1. Parasites Vectors 17, 376 (2024). https://doi.org/10.1186/s13071-024-06455-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s13071-024-06455-7

Keywords

Parasites & Vectors

ISSN: 1756-3305

Contact us